
https://www.science.org/content/blog-post/against-panic
# Against Panic (November 2009)

## 1. SUMMARY

This commentary addresses widespread anxiety in the biotechnology industry during a period of extensive layoffs and structural changes. The author argues against despair by making several key points: there will continue to be strong demand for new medicines due to an aging global population and the cost-effectiveness of pharmaceutical treatments compared to alternatives like surgery; small molecules will remain important alongside the gradual rise of biologics due to oral administration advantages; the industry faces an unsustainable model where high R&D costs and low productivity create pressure for cost-cutting; and the path forward lies in improving drug discovery efficiency rather than austerity measures. The author notes that even modest improvements to the 90% clinical failure rate could double market output and argues that the massive demand for treatments will drive solutions to emerge.

## 2. HISTORY

The period following 2009 saw significant evolution in the pharmaceutical and biotechnology landscape, though many fundamental challenges persisted. Small molecule drugs continued to dominate pharmaceutical portfolios, but biologics captured an increasing market share, with monoclonal antibodies and other protein therapeutics becoming major revenue drivers. Drugs like Humira (adalimumab) exemplified biologics' commercial success, though debates continued about development costs versus small molecules.

Several trends validated the author's concerns: R&D productivity remained stubbornly low, with failure rates staying high throughout the 2010s despite technological advances. The industry did see consolidation continue, with mergers and outsourcing to contract research organizations (CROs) accelerating as cost pressures mounted. However, FDA approvals actually increased during the 2010s, particularly for rare diseases and cancer treatments, suggesting some efficiency gains.

The opioid crisis that emerged post-2009 led to intensified scrutiny of pharmaceutical marketing practices, resulting in regulatory changes and legal settlements that impacted promotional strategies. Additionally, the 2010s saw the rise of immunotherapy in oncology, CAR-T cell therapies, and gene therapies—breakthrough areas not widely anticipated in 2009 that became major focus areas.

## 3. PREDICTIONS

• **Prediction: Ongoing need for new medicines driven by aging populations and cost-effectiveness**  
  **Outcome:** Partially accurate. The stated demographic and economic drivers remained valid throughout the 2010s and beyond, contributing to sustained market growth. However, the relationship between pharmaceutical treatment and overall healthcare costs became more complex; while drug spending increased, questions emerged about the sustainability of premium pricing for specialty drugs.

• **Prediction: Small molecules will remain important, with biologics gradually increasing their market share**  
  **Outcome:** Accurate. Small molecules continued to dominate the pipeline and market, while biologics grew substantially. By the mid-2010s, biologics accounted for roughly 25-30% of pharmaceutical spending, though small molecules still represented the majority of prescriptions due to their convenience and cost advantages, exactly as predicted.

• **Prediction: Industry pressures will force improvements in drug discovery efficiency**  
  **Outcome:** Mixed success. While there were advances in areas like high-throughput screening, computer-aided drug design, and biomarker development, the fundamental 90% failure rate cited by the author remained largely unchanged. The industry continued struggling with R&D productivity, leading to sustained focus on external innovation through licensing and acquisitions rather than pure internal discovery.

• **Prediction: Improving from 90% to 80% clinical failure rate would double new drug output**  
  **Outcome:** The arithmetic here proved correct—a 10 percentage point improvement would indeed double success rates. However, achieving this reduction in failure rates remained elusive. Throughout the 2010s, industry-wide success rates saw modest improvements in early-phase trials but not the dramatic gains suggested.

• **Prediction: Solutions will emerge because market demand is too great**  
  **Outcome:** Partially accurate. The industry did adapt through various mechanisms—increased M&A activity, greater focus on specialty medicines, expanded use of real-world evidence, and improved clinical trial designs. However, many fundamental discovery challenges persisted, and the "solution" often involved shifting costs and risks rather than fundamentally solving underlying scientific problems.

• **Prediction: Cost-cutting and aggressive marketing are short-term solutions with long-term problems**  
  **Outcome:** This proved prescient. Companies that relied heavily on cost-cutting often faced pipeline gaps years later, while aggressive marketing tactics, particularly around opioids, led to major legal and reputational consequences that emerged prominently in the late 2010s.

## 4. INTEREST

Rating: **6/10**

This article provides a reasonably insightful snapshot of industry sentiment during a turbulent period, and several predictions about the continued importance of small molecules and gradual biologics growth proved accurate. However, it misses the emergence of transformative therapeutic areas like immunotherapy and gene therapy that would reshape the industry, and the piece lacks the prescience needed for a higher rating. The analysis remains grounded but doesn't offer particularly novel insights beyond common industry observations of the time.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20091111-against-panic.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_